Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Evotec, UCB in Multi-Target Collaboration | Contract Pharma

What are you searching for?

Sign in
Breaking News

Evotec, UCB in Multi-Target Collaboration

Will identify small molecules against immunology targets

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Evotec AG has entered into a multi-target drug discovery collaboration with UCB in the field of immunology. Evotec will apply its drug discovery expertise to identify small molecules against a selected number of targets, then optimize a preclinical candidate. Evotec will receive research funding and will receive early stage discovery, preclinical and clinical milestones, as well as royalties on sales of any approved drugs from the collaboration. Financial details were not disclosed.
 
Dr. Werner Lanthaler, chief executive officer of Evotec, said, “We are extremely pleased that UCB has again selected Evotec to collaborate on this second significant Drug Discovery Collaboration. This integrated drug discovery deal showcases our broad target class expertise coupled with our industry-leading platform. We look forward to a fruitful collaboration with our scientific colleagues and friends at UCB.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics